NAD+, plasmalogens and the case for translational longevity science.

Longevity science has no shortage of promising molecules. NAD+ precursors, plasmalogens and marine peptides each have a credible mechanistic story. The hard part is not the discovery — it is enzymatic synthesis at purity and scale, cost-efficient manufacturing, and the regulatory pathway that lets a product reach people.

The group's bioscience platform is built around that translational step: a contracted research relationship with the University of Adelaide for enzymatic NMN, and pre-clinical collaborations for plasmalogens and tuna-derived peptides. The intent is to manufacture in Australia and distribute globally, with the science intact through scale-up.